SelectScience
Join Free
NewsLife Sciences

Curetis Group subsidiary Ares Genetics signs R&D and option agreement with leading global IVD corporation

Curetis N.V

R&D collaboration to develop NGS-based predictive antibiotic resistance testing powered by ARESdb

19 Sept 2019
Jay Leech
Marketing / Sales

Industry news

Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level molecular diagnostic solutions, has announced that its wholly-owned subsidiary Ares Genetics GmbH (“Ares Genetics”), Vienna, Austria, has entered into a multi-phase partnership with an undisclosed leading global in vitro diagnostics corporation (the “Partner”) to jointly develop diagnostic solutions for infectious disease testing based on next-generation sequencing (“NGS”) technology. The companies signed an R&D and option agreement for the first phase of the partnership.

The partnership follows the successful completion of a feasibility study in which Ares Genetics correctly identified 100% of the pathogen species and successfully predicted antibiotic resistance for over 50 drug/pathogen combinations in line with FDA requirements (<1.5% very major error, i.e. misclassification of resistant isolates as susceptible and <3 % major error, i.e. misclassification of susceptible isolates as resistant).

In a first phase of the collaboration expected to take about 12 months, the parties will further enrich ARESdb with a focus on certain pathogens relevant in a first, undisclosed infectious disease indication. Additional clinical isolates of such pathogens will be sequenced by Ares Genetics at its recently established NGS laboratory in Vienna, Austria. Based on this enlarged and enriched dataset, Ares Genetics will further optimize the algorithms for predictive antibiotic resistance testing for drug/pathogen combinations particularly relevant in the targeted indication to enable NGS-based infectious disease diagnostics.

Under the initial agreement signed, the Partner will fully fund Ares Genetics’ research and development activities for the genotypic and phenotypic characterization of additional bacterial strains to augment ARESdb and the development of optimized algorithms for predicting antibiotic resistance. Furthermore, in return for an undisclosed up-front option fee, the Partner obtains a right of first negotiation for an exclusive human clinical diagnostic use license to ARESdb and the ARES Technology Platform for the term of the agreement plus three months.

For more science news, straight to your inbox, join SelectScience today >>

Links

Curetis N.VCompany website

Tags

Next Generation SequencingNext-generation sequencing (NGS), also known as whole-genome sequencing, high-throughput sequencing and massive parallel sequencing, produces and analyses thousands to millions of nucleotide sequences at once. Sequencing systems operate via varying technologies depending on the manufacturer, including sequencing by synthesis, ligation, pyrosequencing, ion semiconductor and single-molecule real-time sequencing. For NGS, library preparation is paramount to successful sequencing. In this section, explore a range of library preparation kits, from targeted, amplicon-based or hybridization-based kits including epigenomic, transcriptomic and genomic workflows to fragmentation kits. Find the best next-generation sequencing products in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.Research and DevelopmentPathogen DetectionPathogen detection is the process of identifying harmful microorganisms, including bacteria, viruses, and fungi, that can cause diseases. Accurate pathogen detection is critical for food safety, public health, and clinical diagnostics. Explore pathogen detection products in our peer-reviewed product directory; compare products, check reviews, and get pricing directly from manufacturers.CollaborationIn Vitro DiagnosticsIn vitro diagnostics (IVD) involve testing samples outside the body, typically in a laboratory, to diagnose diseases or conditions. IVD technologies include blood tests, molecular assays, and other bodily fluid tests, enabling accurate diagnosis and monitoring of diseases. These tests are essential for guiding treatment decisions in clinical settings. Browse our peer-reviewed product directory to find the best IVD solutions; compare products, check reviews, and get pricing directly from manufacturers.Molecular DiagnosticsMolecular diagnostics use an individual’s genetic code and gene expression to diagnose and monitor diseases. The technique is used increasingly in the field of infectious diseases and oncology, as well as areas such as coagulation, HLA typing and pharmacogenomics. Molecular diagnostics plays a pivotal role in personalized medicine.Antibiotic ResistanceAntibiotic resistance poses a significant threat to public health driving innovation and change through antibiotic stewardship efforts. Ongoing research and diagnostic efforts focus on new treatments and detection methods. Explore antibiotic resistance research and diagnostic tools in our peer-reviewed product directory; compare products, check reviews, and get pricing directly from manufacturers.Infectious DiseasesInfectious diseases are caused by pathogens such as bacteria, viruses, and fungi. Effective detection, prevention, and treatment are crucial to control outbreaks and improve public health. Diagnostic tools, vaccines, and antimicrobial treatments are essential components of managing these diseases. Research into emerging pathogens and resistance patterns continues to evolve. Browse our peer-reviewed product directory to find the best diagnostic tools, prevention solutions, and treatment options; compare products, read customer reviews, and get pricing directly from manufacturers.

Related articles